As per Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) the U.S. government trial on remdesivir safety and efficacy has shown a recovery rate 31% faster as compared to placebo, these are preliminary trial results and are highly significant. The experimental drug by Gilead Sciences Inc. (GILD.O) could become the standard of care for COVID-19 said, Dr Fauci. The FDA needs to be completely sure on the safety and efficacy of the drug even before granting emergency authorization. Out of 1,063 COVID-19 patients, the remdesivir group recovered in 11 days and placebo group required 15 days to recover. The patients in remdesivir showed a better survival rate than in the placebo group. The complete trial results are expected to be out by mid-May. Dr Aneesh Mehta, a researcher on the NIH trial from Emory University School of Medicine in Atlanta said that complete data will better clarify the outcomes.